Piper Sandler analyst Christopher Raymond downgraded Deciphera to Neutral from Overweight with a price target of $25.60, up from $23, after the company entered a definitive merger agreement under which ONO Pharmaceutical will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter